Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder shows promise in reducing cannabis consumption.

Aelis Farma has released results from its Phase 2B clinical study of AEF0117, targeting individuals with Cannabis Use Disorder (CUD). The study aims to evaluate the efficacy of AEF0117 in reducing cannabis consumption. Indivior PLC also provided insights into these findings, highlighting their significance in addressing CUD. Further details on the efficacy and safety of AEF0117 are anticipated to inform future treatment options.

September 04, 2024
6 Articles